The ongoing Phase 2 trial of fractionated gemtuzumab ozogamicin (GO for MRD) is sponsored by the University of Washington, in collaboration with Pfizer. This trial aims to evaluate the efficacy of gemtuzumab ozogamicin in eradicating measurable residual disease (MRD) in AML patients. The targeted therapy approach may position this asset favorably in the competitive landscape, particularly as the treatment of AML continues to evolve with a focus on precision medicine. The successful outcome of this trial could enhance the market potential for gemtuzumab ozogamicin, especially given the unmet need for effective therapies in MRD-positive AML patients. The trial is currently recruiting, with an estimated completion date in December 2026, which may allow for timely entry into the market if results are favorable.